Skip to main content
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: Clin Cancer Res. 2013 Oct 4;19(22):10.1158/1078-0432.CCR-13-1848. doi: 10.1158/1078-0432.CCR-13-1848

Figure 2. Tumor markers in HCL patients after BR.

Figure 2

Serum levels of soluble CD22 (sCD22) (A, B) and soluble CD25 (sCD25) (C, D) are shown for patients achieving clearance of HCL in the marrow (A, C) and for patients with partial HCL clearing after BR (B, D).